查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134988

全球視神經脊髓炎流行病學分析與預測 - 2026 年

Global Neuromyelitis Optica Epidemiology Analysis and Forecast, 2026
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計全球視神經脊髓炎的盛行率將以 3.1% 的複合年成長率成長，從 2026 年的 20 萬例增加到 2035 年的 27 萬例。

視神經脊髓頻譜疾病（NMOSD）是一種罕見的自體免疫發炎性疾病，主要涉及中樞神經系統，涉及視神經和脊髓，導致反覆發作的視神經炎、橫貫性脊髓炎、癱瘓、視力障礙和長期神經功能障礙。水通道蛋白4（AQP4）抗體的發現顯著提高了診斷準確性和疾病分類，使NMOSD更容易與多發性硬化症鑑別，並有助於更可靠的流行病學評估。隨著人們對NMOSD的認知和診斷能力的不斷提高，流行病學分析在醫療保健規劃、臨床試驗招募、市場預測和罕見疾病管理中變得越來越重要。

流行病學分析能夠全面深入地揭示疾病的流行情況、發病率、確診患者群體、人口分佈、血清亞型、區域疾病負擔以及長期患者預測。這些分析有助於製藥公司、生技公司、醫療服務提供者、政策制定者、研究人員和投資者評估治療機會並制定未來的醫療保健策略。

市場促進因素

對此疾病的認知提高以及診斷能力的提升

  • 市場促進因素之一是人們對視神經脊髓炎譜系障礙（NMOSD）作為一種獨立的自體免疫神經系統疾病的認知不斷提高。醫生對該疾病認知的提高、診斷標準的更新以及AQP4抗體檢測的廣泛應用，顯著提高了診斷率，並減少了與多發性硬化症的誤診。
  • 早期診斷能夠實現更準確的流行病學追蹤，並有助於及時治療性介入。

擴大流行病學調查範圍

  • 對罕見疾病登記、觀察性研究和基於人群的調查投入的增加，正在提高全球流行病學數據的品質。國家登記處和國際合作調查正在提供關於疾病盛行率、發病率、患者人口統計特徵和長期預後的更全面的資訊。
  • 這些措施加強了疾病監測，並支持制定循證醫療保健計劃。

精準醫療的需求日益成長

  • 標靶生物製藥的出現，使得根據抗體狀態、疾病嚴重程度、年齡、性別和地理分佈對患者進行詳細細分的需求日益增加。
  • 準確的流行病學分析能夠幫助製藥公司估算目標患者群體，最佳化臨床試驗參與者招募，並支持其商業化策略。

診斷技術的進步

  • 抗體檢測、磁振造影(MRI)、分子診斷和生物標記識別的進步提高了病例檢測的準確性，並減少了診斷延遲。
  • 高靈敏度臨床檢測的引入，提高了已開發國家和新興國家醫療保健市場的流行病學準確性。

市場限制因素

被歸類為罕見疾病

  • NMOSD 仍然是一種相對罕見的神經系統疾病，這限制了大規模流行病學資料集的獲取，並對長期人口預測提出了挑戰。

診斷方面的區域差異

  • 醫療保健基礎設施、專科醫生資源、診斷能力和報告系統方面的差異，導致各國和地區在疾病識別方面存在差異。

缺乏長期數據

  • 雖然流行病學研究已大幅擴展，但在許多地區，特別是中低收入國家，有關長期自然進展的數據仍然有限。

流行病學和患者族群調查結果

  • 儘管與其它神經系統疾病相比，NMOSD 的全球疾病負擔仍然相對較低，但由於其慢性復發性以及可能導致嚴重殘疾，該疾病對患者產生了重大影響。
  • 目前的流行病學研究估計，視神經脊髓炎譜系疾病（NMOSD）的盛行率約為每10萬人0.5至10例，年發生率為每10萬人0.03至0.88例，但不同地區和種族之間存在顯著差異。非裔和亞裔族群的盛行率較高，而白種族群的盛行率通常較低。
  • 視神經脊髓炎譜系疾病（NMOSD）患者以女性居多，尤其在AQP4抗體陽性患者中更為明顯，且多發生於中年。在大多數研究族群中，AQP4抗體陽性患者的盛行率顯著高於抗體陰性患者。
  • 隨著診斷測試的不斷進步和人們對該疾病的認知不斷提高，預計在整個預測期內，確診患者的數量將穩步增加。

目錄

第1章執行摘要

  • 報告摘要
  • 主要發現
  • 視神經脊髓炎頻譜疾病（NMOSD）的流行病學概述
  • 關於發病率和盛行率的關鍵點
  • 目前治療狀況概述
  • 管道和創新概覽
  • 主要成長機遇
  • 前景

第2章 疾病與流行病學分析

  • 視神經脊髓炎頻譜障礙（NMOSD）簡介
  • 該疾病的定義和臨床特徵
  • 疾病分類的歷史變化
  • 病因和危險因子
  • 免疫發病機制
    • 自體免疫機制
    • 水通道蛋白4 (AQP4) 抗體的作用
    • 與髓鞘少突膠質細胞糖蛋白 (MOG) 抗體相關的疾病和鑑別診斷
  • 疾病的徵兆和症狀
  • 診斷標準和指南
  • 疾病負擔對生活品質的影響
  • 流行病學概述
    • 患者總數
    • 新增病例總數
    • 確診病例數
    • 性別流行病學
    • 特定年齡流行病學
    • AQP4-IgG陽性族群
    • AQP4-IgG陰性族群
    • MOG抗體相關疾病患者族群
  • 流行病學預測

第3章 市場動態

  • 市場概覽
  • 市場促進因素
    • 對該疾病的認知提高和診斷率的提高
    • 提高標靶生技藥品的可及性
    • 診斷技術的進步
  • 市場限制因素
    • 高昂的醫療費用
    • 新興市場的進入限制
    • 罕見疾病診斷面臨的挑戰
  • 市場機遇
    • 新型免疫療法的推廣
    • 基於生物標記的個人化醫療
    • 進入新興市場
  • 波特五力分析
  • PESTLE分析

第4章 商業和市場進入

  • 市場進入概覽
  • 定價分析
  • 贖回方案
  • 健康科技評估（HTA）的發展趨勢
  • 患者支持計劃
  • 罕見疾病防治的資金籌措工作
  • 分銷和供應鏈概述

第5章：創新與通路的現狀

  • 創新概覽
  • 新的治療方法
    • 補體抑制劑
    • 抗CD19療法
    • 抗IL-6受體療法
    • FcRn抑制劑
  • 管道概覽
  • 一期臨床試驗候選藥物
  • 二期管線候選藥物
  • 處於 III 期臨床試驗階段的候選藥物
  • 按作用機制分類的開發平臺
  • 處理管線
    • 單株抗體
    • 重組蛋白
    • 生物製劑
  • 臨床試驗現狀
  • 許可、合作研究和策略夥伴關係

第6章 當前治療狀況

  • 目前治療模式
  • 急性癲癇發作的管理
    • 皮質類固醇
    • 血漿置換
    • 靜脈注射免疫球蛋白
  • 維持治療
  • 已通過核准療法概述
    • Soliris（Eculizumab）
    • Ultomiris (Lavrizma)
    • Apprisna（inebilizumab）
    • Ensprin（沙曲珠單抗）
  • 治療流程
  • 未滿足的臨床需求
  • 治療的未來趨勢

第7章：全球視神經脊髓炎流行病學報告：市場規模及預測

  • 市場規模概覽
  • 過往市場分析
  • 預測性調查方法
  • 市場預測：按價值
  • 市場預測：按流通量
  • 基於流行病學的市場預測
  • 市場吸引力分析

第8章 全球視神經脊髓炎流行病學報告市場細分

  • 治療類型
    • 急性復發的治療
    • 維持治療
  • 藥物類別
    • 補體抑制劑
    • B細胞消融療法
    • 抗IL-6受體單株抗體
    • 其他
  • 適應症
    • AQP4-IgG陽性視神經脊髓炎譜系疾病
    • AQP4-IgG 陰性視神經脊髓炎譜系疾病
  • 透過行政途徑
    • 靜脈
    • 皮下
    • 口服
  • 最終用戶
    • 醫院
    • 專科診所
    • 居家照護環境
    • 其他
  • 透過分銷管道
    • 醫院藥房
    • 零售藥局和專科藥局
    • 網路藥房

第9章 區域分析（區域層級）

  • 北美洲
    • 市場規模和成長
    • 流行病學趨勢
    • 需求要素
    • 法規概述
    • 競爭強度
  • 歐洲
    • 市場規模和成長
    • 流行病學趨勢
    • 需求要素
    • 法規概述
    • 競爭強度
  • 亞太地區
    • 市場規模和成長
    • 流行病學趨勢
    • 需求促進因素
    • 法規概述
    • 競爭強度
  • 拉丁美洲
    • 市場規模和成長
    • 流行病學趨勢
    • 需求促進因素
    • 法規概述
    • 競爭強度
  • 中東和非洲
    • 市場規模和成長
    • 流行病學趨勢
    • 需求推動要素
    • 法規概述
    • 競爭強度

第10章 主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 法規概述
  • 美國FDA框架
  • 歐盟－關於孤兒藥和歐洲藥品管理局（EMA）的法規
  • 日本 - PMDA法規結構
  • 印度—關於CDSCO和罕見疾病的政策
  • 中國 - NMPA法規結構
  • 孤兒藥認定及獎勵
  • 定價和兌換政策
  • 未來監理趨勢

第12章 競爭格局

  • 市佔率分析
  • 競爭基準
  • 產品定位分析
  • 管道競爭性評估
  • 策略舉措
    • 夥伴關係與合作
    • 併購
    • 授權協議
    • 區域擴大策略

第13章：公司簡介

  • AstraZeneca
  • Amgen
  • Roche Holding
  • Chugai Pharmaceutical
  • Mitsubishi Tanabe Pharma Corporation
  • Argenx
  • HanAll Biopharma
  • Alexion Pharmaceuticals
  • Horizon Therapeutics
  • Viela Bio

第14章：未來展望

  • 市場成長前景
  • 治療方面的新趨勢
  • 管道驅動的市場演變
  • 個性化醫療的前景
  • 競爭格局展望
  • 策略建議

第15章：調查方法

  • 調查方法
  • 數據來源
  • 流行病學建模方法
  • 預測調查方法
  • 數據檢驗和三角測量
  • 先決條件和限制
  • 簡稱和定義
簡介目錄
Product Code: KSI-008872

The Global Neuromyelitis Optica prevelance is forecast to grow at a CAGR of 3.1%, reaching 0.27 million patients in 2035 from 0.20 million patients in 2026.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system that primarily affects the optic nerves and spinal cord, leading to recurrent episodes of optic neuritis, transverse myelitis, paralysis, visual impairment, and long-term neurological disability. The discovery of aquaporin-4 (AQP4) antibodies has significantly improved diagnostic accuracy and disease classification, allowing better differentiation from multiple sclerosis and supporting more reliable epidemiological assessments. As awareness and diagnostic capabilities continue to improve, epidemiology analysis has become increasingly important for healthcare planning, clinical trial recruitment, commercial forecasting, and rare disease management.

Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic distribution, serological subtypes, regional disease burden, and long-term patient forecasts. These analyses support pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, researchers, and investors in evaluating treatment opportunities and planning future healthcare strategies.

Market Drivers

Growing Disease Awareness and Improved Diagnosis

  • One of the primary drivers of market growth is the increasing recognition of NMOSD as a distinct autoimmune neurological disorder. Greater physician awareness, updated diagnostic criteria, and widespread availability of AQP4 antibody testing have significantly improved diagnosis rates and reduced misclassification with multiple sclerosis.
  • Earlier diagnosis enables more accurate epidemiological tracking and supports timely therapeutic intervention.

Expansion of Epidemiological Research

  • Growing investments in rare disease registries, observational studies, and population-based research are improving the quality of epidemiological data worldwide. National registries and international collaborations are generating more comprehensive information regarding disease prevalence, incidence, patient demographics, and long-term outcomes.
  • These initiatives are strengthening disease surveillance and supporting evidence-based healthcare planning.

Increasing Demand for Precision Medicine

  • The emergence of targeted biologic therapies has increased the need for detailed patient segmentation based on antibody status, disease severity, age, gender, and geographic distribution.
  • Accurate epidemiological analysis enables pharmaceutical companies to estimate eligible patient populations, optimize clinical trial recruitment, and support commercialization strategies.

Advancements in Diagnostic Technologies

  • Improvements in antibody assays, magnetic resonance imaging (MRI), molecular diagnostics, and biomarker identification are enhancing case detection and reducing diagnostic delays.
  • The adoption of high-sensitivity laboratory testing continues to improve epidemiological accuracy across both developed and emerging healthcare markets.

Market Restraints

Rare Disease Status

  • NMOSD remains a relatively uncommon neurological disorder, limiting the availability of large-scale epidemiological datasets and creating challenges for long-term population forecasting.

Regional Variability in Diagnosis

  • Differences in healthcare infrastructure, access to specialist care, diagnostic capabilities, and reporting systems contribute to variations in disease identification across countries and regions.

Limited Long-Term Data

  • Although epidemiological research has expanded considerably, long-term natural history data remain limited in many regions, particularly within low- and middle-income countries.

Epidemiology and Patient Population Insights

  • The global burden of NMOSD remains relatively low compared with other neurological disorders; however, the disease has a significant impact on patients due to its chronic, relapsing nature and potential for severe disability.
  • Current epidemiological studies estimate that NMOSD prevalence generally ranges from approximately 0.5 to 10 cases per 100,000 population, while annual incidence ranges from 0.03 to 0.88 cases per 100,000 population, with considerable variation across geographic regions and ethnic groups. Higher prevalence has been reported among individuals of African and Asian ancestry, while lower prevalence has generally been observed in White populations.
  • Women account for the majority of NMOSD cases, particularly among AQP4 antibody-positive patients, with disease onset most commonly occurring during middle adulthood. The prevalence of AQP4-seropositive disease is substantially higher than seronegative disease across most studied populations.
  • As improvements in diagnostic testing and disease awareness continue, the diagnosed patient population is expected to increase steadily throughout the forecast period.

Technology and Segment Insights

  • The global NMOSD epidemiology analysis market can be segmented by disease subtype, antibody status, age group, gender, data source, end user, and geography.
  • By disease subtype, the market includes AQP4 antibody-positive NMOSD, myelin oligodendrocyte glycoprotein (MOG)-associated disease, seronegative NMOSD, and related autoimmune demyelinating disorders.
  • By antibody status, the market includes AQP4-positive, MOG-positive, and double-seronegative patient populations. AQP4-positive patients currently represent the largest epidemiological segment.
  • By age group, the market includes pediatric, adult, and elderly patient populations. Adult patients account for the largest share, although pediatric cases remain clinically significant.
  • By gender, the market includes male and female populations, with females representing a substantially higher proportion of diagnosed patients.
  • By data source, the market includes hospital databases, electronic health records, patient registries, insurance claims databases, laboratory databases, and population-based epidemiological studies.
  • By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms.
  • Advancements in artificial intelligence, predictive analytics, digital health platforms, and real-world evidence systems are improving patient identification, disease surveillance, and long-term epidemiological forecasting.

Regional Insights

  • North America remains a leading market for NMOSD epidemiology analysis due to advanced diagnostic infrastructure, established patient registries, and strong rare disease research programs.
  • Europe represents another significant market supported by collaborative neurological research networks, comprehensive healthcare systems, and increasing epidemiological surveillance.
  • Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing availability of antibody testing, expanding clinical research activity, and rising awareness of autoimmune neurological disorders. Countries such as Japan, China, South Korea, and India continue to strengthen rare disease diagnosis and reporting capabilities.
  • Latin America and the Middle East & Africa are gradually improving epidemiological surveillance through expanding healthcare access, improved laboratory diagnostics, and participation in international rare disease research initiatives.

Competitive Landscape

  • The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, academic research institutions, pharmaceutical companies, biotechnology firms, and healthcare consulting organizations.
  • Industry participants continue to invest in disease registries, real-world evidence generation, digital epidemiology platforms, biomarker research, and advanced healthcare analytics. Strategic collaborations between pharmaceutical companies, academic centers, patient advocacy organizations, and government agencies are improving data quality and strengthening epidemiological research capabilities.

Future Outlook

  • The future NMOSD epidemiology analysis market is expected to be driven by continued improvements in diagnostic technologies, expansion of global patient registries, increasing adoption of precision medicine, and greater integration of real-world evidence into healthcare decision-making.
  • Artificial intelligence, genomic analytics, biomarker discovery, and digital disease surveillance platforms are expected to enhance epidemiological forecasting and improve understanding of disease burden across different populations.
  • As awareness continues to increase and diagnostic capabilities improve worldwide, more accurate estimates of disease prevalence, incidence, and patient demographics are expected to support clinical development and healthcare planning.

Conclusion

  • The global Neuromyelitis Optica epidemiology analysis market is poised for steady growth through 2035, supported by expanding epidemiological research, improved diagnostic technologies, increasing disease awareness, and growing investment in rare neurological disease management. Although NMOSD remains a rare disorder, advances in antibody testing, patient registries, real-world evidence, and digital health technologies are significantly improving disease surveillance and patient identification. As more comprehensive epidemiological data become available, stakeholders across the healthcare ecosystem will be better positioned to support clinical research, optimize healthcare resource allocation, and improve long-term patient outcomes.

Key Benefits of this Report

  • Insightful Analysis: Comprehensive evaluation of global NMOSD prevalence, incidence, diagnosed patient populations, and epidemiological trends.
  • Competitive Landscape: Understand regional disease burden, patient demographics, and evolving epidemiological research.
  • Market Drivers and Future Trends: Assess factors influencing disease diagnosis, patient identification, and future population growth.
  • Actionable Recommendations: Support healthcare planning, clinical trial recruitment, commercialization strategies, and investment decisions.
  • Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

  • Epidemiological forecasting, patient population assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, and commercialization planning.

Report Coverage

  • Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
  • Global, regional, and country-level epidemiological analysis and forecasts
  • Prevalence, incidence, diagnosed patient population, and demographic segmentation
  • Disease subtype, antibody status, and regional burden assessment
  • Competitive intelligence, patient registry analysis, and future market opportunity outlook.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Overview
  • 1.2 Key Findings
  • 1.3 Epidemiology Snapshot of Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • 1.4 Incidence and Prevalence Highlights
  • 1.5 Treatment Landscape Overview
  • 1.6 Pipeline and Innovation Snapshot
  • 1.7 Key Growth Opportunities
  • 1.8 Future Outlook

2. Disease & Epidemiology Analysis

  • 2.1 Introduction to Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • 2.2 Disease Definition and Clinical Characteristics
  • 2.3 Historical Evolution of Disease Classification
  • 2.4 Etiology and Risk Factors
  • 2.5 Immunopathogenesis
    • 2.5.1 Autoimmune Mechanisms
    • 2.5.2 Role of Aquaporin-4 (AQP4) Antibodies
    • 2.5.3 Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and Differentiation
  • 2.6 Disease Signs and Symptoms
  • 2.7 Diagnostic Criteria and Guidelines
  • 2.8 Disease Burden and Quality of Life Impact
  • 2.9 Epidemiology Overview
    • 2.9.1 Total Prevalent Cases
    • 2.9.2 Total Incident Cases
    • 2.9.3 Diagnosed Prevalent Cases
    • 2.9.4 Gender-wise Epidemiology
    • 2.9.5 Age-wise Epidemiology
    • 2.9.6 AQP4-IgG Positive Population
    • 2.9.7 AQP4-IgG Negative Population
    • 2.9.8 MOG Antibody-associated Disease Population
  • 2.10 Epidemiology Forecast

3. Market Dynamics

  • 3.1 Market Overview
  • 3.2 Market Drivers
    • 3.2.1 Rising Disease Awareness and Diagnosis Rates
    • 3.2.2 Increasing Availability of Targeted Biologics
    • 3.2.3 Advancements in Diagnostic Technologies
  • 3.3 Market Restraints
    • 3.3.1 High Treatment Costs
    • 3.3.2 Limited Access in Emerging Markets
    • 3.3.3 Diagnostic Challenges in Rare Diseases
  • 3.4 Market Opportunities
    • 3.4.1 Expansion of Novel Immunotherapies
    • 3.4.2 Biomarker-based Personalized Medicine
    • 3.4.3 Emerging Markets Penetration
  • 3.5 Porter's Five Forces Analysis
  • 3.6 PESTLE Analysis

4. Commercial & Market Access

  • 4.1 Market Access Overview
  • 4.2 Pricing Analysis
  • 4.3 Reimbursement Scenario
  • 4.4 Health Technology Assessment (HTA) Trends
  • 4.5 Patient Assistance Programs
  • 4.6 Rare Disease Funding Initiatives
  • 4.7 Distribution and Supply Chain Overview

5. Innovation & Pipeline Landscape

  • 5.1 Innovation Overview
  • 5.2 Emerging Therapeutic Approaches
    • 5.2.1 Complement Inhibitors
    • 5.2.2 Anti-CD19 Therapies
    • 5.2.3 Anti-IL-6 Receptor Therapies
    • 5.2.4 FcRn Inhibitors
  • 5.3 Pipeline Landscape Overview
  • 5.4 Phase I Pipeline Candidates
  • 5.5 Phase II Pipeline Candidates
  • 5.6 Phase III Pipeline Candidates
  • 5.7 Pipeline by Mechanism of Action
  • 5.8 Pipeline by Modality
    • 5.8.1 Monoclonal Antibodies
    • 5.8.2 Recombinant Proteins
    • 5.8.3 Biologics
  • 5.9 Clinical Trial Landscape
  • 5.10 Licensing, Collaborations, and Strategic Alliances

6. Treatment Landscape

  • 6.1 Current Treatment Paradigm
  • 6.2 Acute Attack Management
    • 6.2.1 Corticosteroids
    • 6.2.2 Plasma Exchange
    • 6.2.3 Intravenous Immunoglobulin
  • 6.3 Maintenance Therapy
  • 6.4 Approved Therapies Overview
    • 6.4.1 Soliris (eculizumab)
    • 6.4.2 Ultomiris (ravulizumab)
    • 6.4.3 Uplizna (inebilizumab)
    • 6.4.4 Enspryng (satralizumab)
  • 6.5 Treatment Algorithm
  • 6.6 Unmet Clinical Needs
  • 6.7 Future Treatment Trends

7. Global Neuromyelitis Optica Epidemiology Report Size & Forecast

  • 7.1 Market Size Overview
  • 7.2 Historical Market Analysis
  • 7.3 Forecast Methodology
  • 7.4 Market Forecast by Value
  • 7.5 Market Forecast by Volume
  • 7.6 Epidemiology-based Market Forecast
  • 7.7 Market Attractiveness Analysis

8. Global Neuromyelitis Optica Epidemiology Report Segmentation

  • 8.1 By Treatment Type
    • 8.1.1 Acute Relapse Treatment
    • 8.1.2 Maintenance Therapy
  • 8.2 By Drug Class
    • 8.2.1 Complement Inhibitors
    • 8.2.2 B-Cell Depleting Therapies
    • 8.2.3 Anti-IL-6 Receptor Monoclonal Antibodies
    • 8.2.4 Others
  • 8.3 By Indication
    • 8.3.1 AQP4-IgG Positive NMOSD
    • 8.3.2 AQP4-IgG Negative NMOSD
  • 8.4 By Route of Administration
    • 8.4.1 Intravenous
    • 8.4.2 Subcutaneous
    • 8.4.3 Oral
  • 8.5 By End User
    • 8.5.1 Hospitals
    • 8.5.2 Specialty Clinics
    • 8.5.3 HomeCare Settings
    • 8.5.4 Others
  • 8.6 By Distribution Channel
    • 8.6.1 Hospital Pharmacies
    • 8.6.2 Retail & Specialty Pharmacies
    • 8.6.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

  • 9.1 North America
    • 9.1.1 Market Size & Growth
    • 9.1.2 Epidemiology Trends
    • 9.1.3 Demand Drivers
    • 9.1.4 Regulatory Overview
    • 9.1.5 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Market Size & Growth
    • 9.2.2 Epidemiology Trends
    • 9.2.3 Demand Drivers
    • 9.2.4 Regulatory Overview
    • 9.2.5 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size & Growth
    • 9.3.2 Epidemiology Trends
    • 9.3.3 Demand Drivers
    • 9.3.4 Regulatory Overview
    • 9.3.5 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Market Size & Growth
    • 9.4.2 Epidemiology Trends
    • 9.4.3 Demand Drivers
    • 9.4.4 Regulatory Overview
    • 9.4.5 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size & Growth
    • 9.5.2 Epidemiology Trends
    • 9.5.3 Demand Drivers
    • 9.5.4 Regulatory Overview
    • 9.5.5 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Regulatory Overview
  • 11.2 United States - FDA Framework
  • 11.3 Europe - EMA and Orphan Drug Regulations
  • 11.4 Japan - PMDA Regulatory Framework
  • 11.5 India - CDSCO and Rare Disease Policies
  • 11.6 China - NMPA Regulatory Framework
  • 11.7 Orphan Drug Designation and Incentives
  • 11.8 Pricing and Reimbursement Policies
  • 11.9 Future Regulatory Trends

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Product Positioning Analysis
  • 12.4 Pipeline Competitiveness Assessment
  • 12.5 Strategic Initiatives
    • 12.5.1 Partnerships and Collaborations
    • 12.5.2 Mergers and Acquisitions
    • 12.5.3 Licensing Agreements
    • 12.5.4 Geographic Expansion Strategies

13. Company Profiles

  • 13.1 AstraZeneca
    • 13.1.1 Company Overview
    • 13.1.2 Approved Products: Soliris (eculizumab), Ultomiris (ravulizumab)
    • 13.1.3 Key Indications
    • 13.1.4 Pipeline Overview
  • 13.2 Amgen
    • 13.2.1 Company Overview
    • 13.2.2 Approved Product: Uplizna (inebilizumab)
    • 13.2.3 Key Indications
    • 13.2.4 Pipeline Overview
  • 13.3 Roche Holding
    • 13.3.1 Company Overview
    • 13.3.2 Approved Product: Enspryng (satralizumab)
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Overview
  • 13.4 Chugai Pharmaceutical
    • 13.4.1 Company Overview
    • 13.4.2 Approved Product: Enspryng (satralizumab)
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Overview
  • 13.5 Mitsubishi Tanabe Pharma Corporation
    • 13.5.1 Company Overview
    • 13.5.2 Approved Product Portfolio
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline Overview
  • 13.6 Argenx
    • 13.6.1 Company Overview
    • 13.6.2 Pipeline Candidate: efgartigimod
    • 13.6.3 Clinical Development Status
    • 13.6.4 Strategic Outlook
  • 13.7 HanAll Biopharma
    • 13.7.1 Company Overview
    • 13.7.2 Pipeline Candidate: batoclimab
    • 13.7.3 Clinical Development Status
    • 13.7.4 Strategic Outlook
  • 13.8 Alexion Pharmaceuticals
    • 13.8.1 Company Overview
    • 13.8.2 Approved Products Portfolio
    • 13.8.3 Key Indications
    • 13.8.4 Strategic Developments
  • 13.9 Horizon Therapeutics
    • 13.9.1 Company Overview
    • 13.9.2 Approved Products Portfolio
    • 13.9.3 Key Indications
    • 13.9.4 Strategic Developments
  • 13.10 Viela Bio
    • 13.10.1 Company Overview
    • 13.10.2 Approved Product: Uplizna (inebilizumab)
    • 13.10.3 Key Indications
    • 13.10.4 Historical and Strategic Developments

14. Future Outlook

  • 14.1 Market Growth Outlook
  • 14.2 Emerging Treatment Trends
  • 14.3 Pipeline-driven Market Evolution
  • 14.4 Personalized Medicine Prospects
  • 14.5 Competitive Outlook
  • 14.6 Strategic Recommendations

15. Methodology

  • 15.1 Research Methodology
  • 15.2 Data Sources
  • 15.3 Epidemiology Modeling Approach
  • 15.4 Forecasting Methodology
  • 15.5 Data Validation and Triangulation
  • 15.6 Assumptions and Limitations
  • 15.7 Abbreviations and Definitions